| CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study | 09/26 11:30 | zacks.com |
| Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 | 09/25 10:45 | globenewswire.com |
| Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 | 09/16 08:01 | globenewswire.com |
| Celldex Therapeutics to Present at Upcoming Investor Conferences | 09/12 16:01 | globenewswire.com |
| Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates | 08/08 18:25 | zacks.com |
| Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update | 08/08 16:01 | globenewswire.com |
| Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria | 07/29 16:01 | globenewswire.com |
| Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria | 07/16 08:01 | globenewswire.com |
| Celldex Therapeutics to Present at Jefferies Healthcare Conference | 06/04 16:01 | globenewswire.com |
| Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024 | 06/02 09:01 | globenewswire.com |